Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X, Scott H, Carlsson SV, Sjoberg DD, Cerundolo L, Lilja H, Prevo R, Rieunier G, Macaulay V, Higgins GS, Verrill CL, Lamb AD, Cunliffe VT, Bountra C, Hamdy FC, Bryant RJ.

Prostate. 2019 Jul;79(10):1079-1089. doi: 10.1002/pros.23817. Epub 2019 May 18.

PMID:
31104332
2.

Organizational innovation for developing new medicines that target aging and age-related conditions.

Ford GA, Lord JM, Ferguson MA, Bountra C, Le Couteur DG.

J Gerontol A Biol Sci Med Sci. 2019 Mar 6. pii: glz062. doi: 10.1093/gerona/glz062. [Epub ahead of print] No abstract available.

PMID:
30838376
3.

An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.

D'Ascenzio M, Pugh KM, Konietzny R, Berridge G, Tallant C, Hashem S, Monteiro O, Thomas JR, Schirle M, Knapp S, Marsden B, Fedorov O, Bountra C, Kessler BM, Brennan PE.

Angew Chem Int Ed Engl. 2019 Jan 21;58(4):1007-1012. doi: 10.1002/anie.201807825. Epub 2018 Dec 27.

4.

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.

Vazquez-Rodriguez S, Wright M, Rogers CM, Cribbs AP, Velupillai S, Philpott M, Lee H, Dunford JE, Huber KVM, Robers MB, Vasta JD, Thezenas ML, Bonham S, Kessler B, Bennett J, Fedorov O, Raynaud F, Donovan A, Blagg J, Bavetsias V, Oppermann U, Bountra C, Kawamura A, Brennan PE.

Angew Chem Int Ed Engl. 2019 Jan 8;58(2):515-519. doi: 10.1002/anie.201810179. Epub 2018 Dec 7.

5.

Donated chemical probes for open science.

Müller S, Ackloo S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, Edwards J, Elkins JM, Fischer C, Frye SV, Gollner A, Grimshaw CE, IJzerman A, Hanke T, Hartung IV, Hitchcock S, Howe T, Hughes TV, Laufer S, Li VM, Liras S, Marsden BD, Matsui H, Mathias J, O'Hagan RC, Owen DR, Pande V, Rauh D, Rosenberg SH, Roth BL, Schneider NS, Scholten C, Singh Saikatendu K, Simeonov A, Takizawa M, Tse C, Thompson PR, Treiber DK, Viana AY, Wells CI, Willson TM, Zuercher WJ, Knapp S, Mueller-Fahrnow A.

Elife. 2018 Apr 20;7. pii: e34311. doi: 10.7554/eLife.34311.

6.

Therapeutics discovery: From bench to first in-human trials.

Al-Hujaily EM, Khatlani T, Alehaideb Z, Ali R, Almuzaini B, Alrfaei BM, Iqbal J, Islam I, Malik S, Marwani BA, Massadeh S, Nehdi A, Alsomaie B, Debasi B, Bushnak I, Noibi S, Hussain S, Wajid WA, Armand JP, Gul S, Oyarzabal J, Rais R, Bountra C, Alaskar A, Knawy BA, Boudjelal M.

Biomed Rep. 2018 Mar;8(3):275-282. doi: 10.3892/br.2018.1052. Epub 2018 Jan 31.

7.

The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.

Bradley AR, Echalier A, Fairhead M, Strain-Damerell C, Brennan P, Bullock AN, Burgess-Brown NA, Carpenter EP, Gileadi O, Marsden BD, Lee WH, Yue W, Bountra C, von Delft F.

Essays Biochem. 2017 Nov 8;61(5):495-503. doi: 10.1042/EBC20170051. Print 2017 Nov 8. Review.

8.

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

Lines KE, Stevenson M, Filippakopoulos P, Müller S, Lockstone HE, Wright B, Grozinsky-Glasberg S, Grossman AB, Knapp S, Buck D, Bountra C, Thakker RV.

Oncogenesis. 2017 May 15;6(5):e332. doi: 10.1038/oncsis.2017.30.

9.

Assessing histone demethylase inhibitors in cells: lessons learned.

Hatch SB, Yapp C, Montenegro RC, Savitsky P, Gamble V, Tumber A, Ruda GF, Bavetsias V, Fedorov O, Atrash B, Raynaud F, Lanigan R, Carmichael L, Tomlin K, Burke R, Westaway SM, Brown JA, Prinjha RK, Martinez ED, Oppermann U, Schofield CJ, Bountra C, Kawamura A, Blagg J, Brennan PE, Rossanese O, Müller S.

Epigenetics Chromatin. 2017 Mar 1;10:9. doi: 10.1186/s13072-017-0116-6. eCollection 2017.

10.

Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE.

Cell Chem Biol. 2017 Mar 16;24(3):371-380. doi: 10.1016/j.chembiol.2017.02.006. Epub 2017 Mar 2.

11.

Establishing a reliable framework for harnessing the creative power of the scientific crowd.

Carter AJ, Donner A, Lee WH, Bountra C.

PLoS Biol. 2017 Feb 15;15(2):e2001387. doi: 10.1371/journal.pbio.2001387. eCollection 2017 Feb.

12.

Accelerating target discovery using pre-competitive open science-patients need faster innovation more than anyone else.

Low E, Bountra C, Lee WH.

Ecancermedicalscience. 2016 Aug 3;10:ed57. doi: 10.3332/ecancer.2016.ed57. eCollection 2016.

13.

Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.

Zhang C, Su ZY, Wang L, Shu L, Yang Y, Guo Y, Pung D, Bountra C, Kong AN.

Biochem Pharmacol. 2016 Oct 1;117:35-45. doi: 10.1016/j.bcp.2016.08.009. Epub 2016 Aug 9.

14.

Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer.

Anand U, Sinisi M, Fox M, MacQuillan A, Quick T, Korchev Y, Bountra C, McCarthy T, Anand P.

Mol Pain. 2016 Jun 20;12. pii: 1744806916654144. doi: 10.1177/1744806916654144. Print 2016.

15.

Open Access Could Transform Drug Discovery: A Case Study of JQ1.

Arshad Z, Smith J, Roberts M, Lee WH, Davies B, Bure K, Hollander GA, Dopson S, Bountra C, Brindley D.

Expert Opin Drug Discov. 2016;11(3):321-32. doi: 10.1517/17460441.2016.1144587. Review.

PMID:
26791045
16.

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.

Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.

J Med Chem. 2016 Feb 25;59(4):1388-409. doi: 10.1021/acs.jmedchem.5b01635. Epub 2016 Jan 7.

17.

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.

Fedorov O, Castex J, Tallant C, Owen DR, Martin S, Aldeghi M, Monteiro O, Filippakopoulos P, Picaud S, Trzupek JD, Gerstenberger BS, Bountra C, Willmann D, Wells C, Philpott M, Rogers C, Biggin PC, Brennan PE, Bunnage ME, Schüle R, Günther T, Knapp S, Müller S.

Sci Adv. 2015 Nov 13;1(10):e1500723. doi: 10.1126/sciadv.1500723. eCollection 2015 Nov.

18.

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, Vecellio ML, Bountra C, Brennan PE, O'Mahony A, Velichko S, Müller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S.

Cancer Res. 2015 Dec 1;75(23):5106-5119. doi: 10.1158/0008-5472.CAN-15-0236. Epub 2015 Nov 9.

19.

Corrigendum: The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Ross R, Roth B, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Nov;11(11):887. doi: 10.1038/nchembio1115-887c. No abstract available.

PMID:
26485080
20.

21(st) Century Cures Act: An Act of Cure or Diagnosis?

Brindley DA, Arshad Z, Luo D, Dopson S, Hollander G, Frost S, Bountra C, Smith JA.

Rejuvenation Res. 2015 Aug;18(4):295-8. doi: 10.1089/rej.2015.1757. No abstract available.

21.

The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Aug;11(8):536-41. doi: 10.1038/nchembio.1867. No abstract available. Erratum in: Nat Chem Biol. 2015 Nov;11(11):887. Nat Chem Biol. 2015 Aug;11(8):541. Roth, Brian [Corrected to Roth, Bryan] and Frederiksen, Mathias [Added].

22.

Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.

Anand U, Yiangou Y, Sinisi M, Fox M, MacQuillan A, Quick T, Korchev YE, Bountra C, McCarthy T, Anand P.

Mol Pain. 2015 Jun 26;11:38. doi: 10.1186/s12990-015-0038-x.

23.

Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.

Chen P, Chaikuad A, Bamborough P, Bantscheff M, Bountra C, Chung CW, Fedorov O, Grandi P, Jung D, Lesniak R, Lindon M, Müller S, Philpott M, Prinjha R, Rogers C, Selenski C, Tallant C, Werner T, Willson TM, Knapp S, Drewry DH.

J Med Chem. 2016 Feb 25;59(4):1410-24. doi: 10.1021/acs.jmedchem.5b00209. Epub 2015 Apr 6.

24.

Preclinical target validation using patient-derived cells.

Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M; SGC Open Source Target-Discovery Partnership.

Nat Rev Drug Discov. 2015 Mar;14(3):149-50. doi: 10.1038/nrd4565. Epub 2015 Feb 20.

PMID:
25722227
25.

Building a roadmap for developing combination therapies for Alzheimer's disease.

Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C.

Expert Rev Neurother. 2015 Mar;15(3):327-33. doi: 10.1586/14737175.2015.996551. Review.

26.

Kruidenier et al. reply.

Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM.

Nature. 2014 Oct 2;514(7520):E2. doi: 10.1038/nature13689. No abstract available.

PMID:
25279927
27.

Lost but making progress--Where will new analgesic drugs come from?

Borsook D, Hargreaves R, Bountra C, Porreca F.

Sci Transl Med. 2014 Aug 13;6(249):249sr3. doi: 10.1126/scitranslmed.3008320. Review.

28.

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Rice ASC, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M; EMA401-003 study group.

Lancet. 2014 May 10;383(9929):1637-1647. doi: 10.1016/S0140-6736(13)62337-5. Epub 2014 Feb 5.

PMID:
24507377
29.

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.

Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9. doi: 10.1073/pnas.1310658110. Epub 2013 Nov 18.

30.

Mutant prolactin receptor and familial hyperprolactinemia.

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV.

N Engl J Med. 2013 Nov 21;369(21):2012-2020. doi: 10.1056/NEJMoa1307557. Epub 2013 Nov 6.

31.

Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states.

Shintre CA, Pike AC, Li Q, Kim JI, Barr AJ, Goubin S, Shrestha L, Yang J, Berridge G, Ross J, Stansfeld PJ, Sansom MS, Edwards AM, Bountra C, Marsden BD, von Delft F, Bullock AN, Gileadi O, Burgess-Brown NA, Carpenter EP.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9710-5. doi: 10.1073/pnas.1217042110. Epub 2013 May 28.

32.

The structural basis of ZMPSTE24-dependent laminopathies.

Quigley A, Dong YY, Pike AC, Dong L, Shrestha L, Berridge G, Stansfeld PJ, Sansom MS, Edwards AM, Bountra C, von Delft F, Bullock AN, Burgess-Brown NA, Carpenter EP.

Science. 2013 Mar 29;339(6127):1604-7. doi: 10.1126/science.1231513.

PMID:
23539603
33.

Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons.

Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, Bountra C, Korchev YE, Anand P.

Eur J Pain. 2013 Aug;17(7):1012-26. doi: 10.1002/j.1532-2149.2012.00269.x. Epub 2012 Dec 17.

34.

A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM.

Nature. 2012 Aug 16;488(7411):404-8. doi: 10.1038/nature11262.

35.

Epigenetic protein families: a new frontier for drug discovery.

Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M.

Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400. doi: 10.1038/nrd3674. Review.

PMID:
22498752
36.

Leveraging crowdsourcing to facilitate the discovery of new medicines.

Norman TC, Bountra C, Edwards AM, Yamamoto KR, Friend SH.

Sci Transl Med. 2011 Jun 22;3(88):88mr1. doi: 10.1126/scitranslmed.3002678.

PMID:
21697527
37.

The precompetitive space: time to move the yardsticks.

Norman T, Edwards A, Bountra C, Friend S.

Sci Transl Med. 2011 Mar 30;3(76):76cm10. doi: 10.1126/scitranslmed.3002399.

PMID:
21451121
38.

Animal models of epigenetic regulation in neuropsychiatric disorders.

Bountra C, Oppermann U, Heightman TD.

Curr Top Behav Neurosci. 2011;7:281-322. doi: 10.1007/7854_2010_104.

PMID:
21225415
39.

Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Sanger GJ, Chang L, Bountra C, Houghton LA.

Therap Adv Gastroenterol. 2010 Sep;3(5):291-305. doi: 10.1177/1756283X10369922.

40.

Prepublication data sharing.

Toronto International Data Release Workshop Authors, Birney E, Hudson TJ, Green ED, Gunter C, Eddy S, Rogers J, Harris JR, Ehrlich SD, Apweiler R, Austin CP, Berglund L, Bobrow M, Bountra C, Brookes AJ, Cambon-Thomsen A, Carter NP, Chisholm RL, Contreras JL, Cooke RM, Crosby WL, Dewar K, Durbin R, Dyke SO, Ecker JR, El Emam K, Feuk L, Gabriel SB, Gallacher J, Gelbart WM, Granell A, Guarner F, Hubbard T, Jackson SA, Jennings JL, Joly Y, Jones SM, Kaye J, Kennedy KL, Knoppers BM, Kyrpides NC, Lowrance WW, Luo J, MacKay JJ, Martín-Rivera L, McCombie WR, McPherson JD, Miller L, Miller W, Moerman D, Mooser V, Morton CC, Ostell JM, Ouellette BF, Parkhill J, Raina PS, Rawlings C, Scherer SE, Scherer SW, Schofield PN, Sensen CW, Stodden VC, Sussman MR, Tanaka T, Thornton J, Tsunoda T, Valle D, Vuorio EI, Walker NM, Wallace S, Weinstock G, Whitman WB, Worley KC, Wu C, Wu J, Yu J.

Nature. 2009 Sep 10;461(7261):168-70. doi: 10.1038/461168a.

41.

Open access chemical and clinical probes to support drug discovery.

Edwards AM, Bountra C, Kerr DJ, Willson TM.

Nat Chem Biol. 2009 Jul;5(7):436-40. doi: 10.1038/nchembio0709-436.

PMID:
19536100
42.

Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach.

Beswick PJ, Blackaby AP, Bountra C, Brown T, Browning K, Campbell IB, Corfield J, Gleave RJ, Guntrip SB, Hall RM, Hindley S, Lambeth PF, Lucas F, Mathews N, Naylor A, Player H, Price HS, Sidebottom PJ, Taylor NL, Webb G, Wiseman J.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14. doi: 10.1016/j.bmcl.2009.02.089. Epub 2009 Feb 27.

PMID:
19523822
43.

Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.

Swarbrick ME, Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4504-8. doi: 10.1016/j.bmcl.2009.02.085. Epub 2009 Feb 26.

PMID:
19520573
44.

Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons.

Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP, Anand P.

Pain. 2008 Sep 15;138(3):667-80. doi: 10.1016/j.pain.2008.06.007. Epub 2008 Aug 9.

PMID:
18692962
45.

Perspectives of Alzheimer's disease treatments.

Davis JB, Bountra C, Richardson J.

Handb Clin Neurol. 2008;89:273-90. doi: 10.1016/S0072-9752(07)01226-2. No abstract available.

PMID:
18631752
46.

Volunteer studies in pain research--opportunities and challenges to replace animal experiments: the report and recommendations of a Focus on Alternatives workshop.

Langley CK, Aziz Q, Bountra C, Gordon N, Hawkins P, Jones A, Langley G, Nurmikko T, Tracey I.

Neuroimage. 2008 Aug 15;42(2):467-73. doi: 10.1016/j.neuroimage.2008.05.030. Epub 2008 May 29.

PMID:
18599315
47.

Cytosine arabinoside affects the heat and capsaicin receptor TRPV1 localisation and sensitivity in human sensory neurons.

Anand U, Otto WR, Bountra C, Chessell I, Sinisi M, Birch R, Anand P.

J Neurooncol. 2008 Aug;89(1):1-7. doi: 10.1007/s11060-008-9585-6. Epub 2008 Apr 15.

PMID:
18414789
48.

Voltage-gated ion channel Nav1.7 innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain).

Yiangou Y, Facer P, Chessell IP, Bountra C, Chan C, Fertleman C, Smith V, Anand P.

Neurosci Lett. 2007 Nov 5;427(2):77-82. Epub 2007 Sep 20.

PMID:
17928139
49.

Supplemental Content

Loading ...
Support Center